Project Grant 2233404
Award Date
9/15/23
Completion Date
8/31/24
Dollars Obligated
$275K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
San Carlos, CA 94070, USA
Similar Awards
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $303,864 to Core Biotherapeutics Inc. to develop a platform for discovering therapeutic drugs that can reprogram molecular networks to treat diseases. The project aims to determine the biological laws driving diseases at the molecular network level and create an algorithm to rapidly identify drug targets. The key goals are to demonstrate that oligonucleotide drug...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,991 to Saber Therapeutics, Inc. will support the development of a new approach to deliver cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The project aims to engineer natural killer (NK) cells with targeted protein degraders (TPDs) against three common AML driver proteins. The resulting NK-TPD cells will be tested for...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant of $305,000 awarded to Redpoint Oncology, Inc. aims to develop and validate a novel platform for targeted cancer therapies. The project seeks to design and synthesize new therapeutic payloads that can selectively target and destroy therapy-resistant cancer cells. Research objectives include testing the effectiveness and selectivity of the payload...
This Project Grant award of $275,000 from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a high-throughput platform for small molecule, in-cell targeting of undruggable proteins via their messenger RNAs (mRNAs). The award aims to create an efficient and cost-effective approach for developing therapeutics for previously undruggable diseases, including hard-to-treat neurodegenerative diseases and highly...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $275,000 to Ubiquitx Inc., a New York-based small business, to develop a programmable, modular therapeutic platform for the direct modification of proteins of interest (POIs) using artificial intelligence, protein engineering, and mRNA therapeutics. The goal is to expand the applications of the company's Chimeric Ligands for Induced Proximity (CLIPS)...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I project under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to develop a next-generation sequencing platform for discovering small molecules that target RNA. The $303,445 award to Endura Therapeutics Inc. in San Diego, CA will establish an assay to detect RNA-drug interactions and identify RNA structures amenable to small molecule binding. The goal is to address...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Om Therapeutics Inc. will support the development of a system to enable the rapid, scalable, and cost-effective discovery of new medicines using machine learning. The project aims to encapsulate proteins and small molecules in millions of miniaturized compartments to screen for interactions that could identify novel drug candidates. The key innovations include...
This National Science Foundation (NSF) SBIR Phase I Project Grant awarded to Eascra Biotech, Inc. is focused on developing and advancing regulatory pathways for space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The $274,990 award, granted on December 15, 2024, aims to demonstrate the comparability of space-manufactured JBNPs to earth-made counterparts, with the goal of revolutionizing cancer treatment by providing a versatile and more...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project grant, awarded to Selight, LLC, aims to develop a rapid diagnostic instrument for assessing the health and viability of chimeric antigen receptor (CAR) T cells prior to their use in cancer immunotherapy. The $304,733 award, effective July 1, 2025 through June 30, 2026, will fund the design, engineering, and prototyping of an optical metabolic...